Loading...

OCUL OCULAR THERAPEUTIX INC Expansion Plans 8-K Filing

CLR

CL

OCULAR THERAPEUTIX INC

(OCUL)

2025 8-K

Clinical Trial Update

Financial Results Announced

Management Change

Clinical Trial Update

FDA Application Update

Financial Results Released

Stock Offering Details

Clinical Trial Updates

Financial Statements

Equity Offerings

Financial Results

Financial Results

CEO Compensation Update

Financial Results

Stock Incentive Plan

Management Appointment

Financial Results Announcement

Annual Meeting Approval

Reduction in Force

Financial Results Announcement

Appointment of Pravin U. Du...

Management Agreement Modifi...

Financial Results Announcement

Private Placement and Manag...

FDA Agreement Modification ...

Public Offering

Financial Results Announcement

Presentation at EURETINA In...

Clinical Trial Initiation

Financial Results Announcement

Annual Meeting Approval

Clinical Trial Results

Financial Results Announcement

Amendment to Credit Agreement

Financial Results Announcement

Earnings Update

External Links:

On September 30, 2025, Ocular Therapeutix, Inc. provided updates on its clinical trials for AXPAXLI, focusing on its treatment for wet age-related macular degeneration and non-proliferative diabetic retinopathy, with top-line results expected in 2026 and 2027.

AI Assistant

OCULAR THERAPEUTIX INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.